Actinium Pharmaceuticals (NYSE:ATNM) Downgraded by StockNews.com to Sell

StockNews.com lowered shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a research note released on Monday morning.

A number of other equities analysts have also recently commented on ATNM. HC Wainwright decreased their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. B. Riley downgraded Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $16.00 to $2.00 in a research note on Wednesday, August 7th. Finally, Maxim Group reduced their target price on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $11.40.

Actinium Pharmaceuticals Price Performance

Shares of NYSE ATNM opened at $1.66 on Monday. Actinium Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $10.24. The company has a market capitalization of $51.79 million, a price-to-earnings ratio of -1.11 and a beta of 0.14. The firm’s 50 day simple moving average is $1.80.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ATNM. Interchange Capital Partners LLC bought a new position in shares of Actinium Pharmaceuticals during the third quarter worth $37,000. The Manufacturers Life Insurance Company purchased a new stake in Actinium Pharmaceuticals in the 2nd quarter worth $92,000. Creative Financial Designs Inc. ADV boosted its holdings in shares of Actinium Pharmaceuticals by 183.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock valued at $120,000 after purchasing an additional 41,250 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Actinium Pharmaceuticals during the second quarter valued at about $142,000. Finally, Rhumbline Advisers increased its holdings in shares of Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the last quarter. 27.50% of the stock is owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).